StockLearn from Clustermicro · Stock Breakout ScannerStockLearn

Nectar Lifesciences (NECLIFE)

Pharma · NSE · end-of-day 2026-10-21

₹11.29

Day change

+2.08%

1-year

-19.9%

From 52-week high

-49.3%

Weinstein stage

Stage 4

Minervini template

1/8

Nectar Lifesciences closed at ₹11.29 on 2026-10-21, down 20% over the past year, 49% below its 52-week high. It meets 1 of 8 conditions of Minervini's trend template; Weinstein's stage analysis reads stage 4 - declining. Over the year its annualised volatility was about 54%, with a largest fall of 58% from a peak.

About Nectar Lifesciences

Nectar Lifesciences Limited manufactures pharmaceutical formulations and active pharmaceutical ingredients serving domestic and international markets. Its business benefits from healthcare demand and the global need for affordable medicines. Expansion of product portfolios, manufacturing capacity and international markets can provide opportunities. Regulatory compliance, product approvals, raw-material costs, pricing pressure, currency movements and competition remain important factors.

Price, RSI and MACD

6M1Y2Y3Y

Price · -7.2% over the period

RSI (14) · 58.9

MACD (12, 26, 9) · histogram +0.10

Price · -18.5% over the period

RSI (14) · 58.9

MACD (12, 26, 9) · histogram +0.10

Price · -71.7% over the period

RSI (14) · 58.9

MACD (12, 26, 9) · histogram +0.10

Price · -54.7% over the period

RSI (14) · 58.9

MACD (12, 26, 9) · histogram +0.10

Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market cap	Sales (TTM)	Net profit (TTM)	P/E	EPS (TTM)	P/B	ROE	Beta
₹219 cr	—	—	—	-11.38	0.39	-39.3%	0.96

Investor methods

Method	Checks	Score	Verdict
Minervini	✗ Close above the 150- and 200-day averages ✗ 150-day above 200-day ✗ 200-day rising for a month ✗ 50-day above the 150- and 200-day ✓ Close above the 50-day ✗ At least 25% above the 52-week low · low 9.30 ✗ Within 25% of the 52-week high · high 22.25 ✗ RS percentile 70 or more · RS 54 Minervini's trend template - the gate the scanner applies.	1/8	1 of 8
Weinstein	Stan Weinstein's stage analysis on the 30-week moving average.		Stage 4 - declining
CAN SLIM	— C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 22.25 ✓ S more volume on up days than down days (50 sessions) · 1.60x ✗ L RS percentile 80 or more · RS 54 — I institutional sponsorship rising (FII + DII) · not yet collected for this stock ✗ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 39% William O'Neil's growth-leader checklist.	1/4	Weak
Darvas	✗ New 52-week high in the last 120 sessions Darvas needs a new 52-week high to start a box.	10/100	No box
Turtle	✗ Close above the prior 55-session high · 13.50 ✓ Close above the prior 20-session high · 11.20 ✗ Close below the prior 20-session low · 10.00 Donchian channel breakout - the Turtle traders' entry.		Breakout (20-day)
Graham	Needs positive earnings and book value.		Not assessable

Each method's own rules, applied to this stock - shown as information, not a buy or sell signal. All were tested on available data.

Pharma sector — top 10 by 1-year return

Stock	1M %	3M %	6M %	1Y %	3Y %	5Y %	P/E	P/B	ROE %	ROCE %	ROA %	D/E	EV/EBITDA	₹ Cr	Sales TTM ₹ Cr	Profit TTM ₹ Cr	EPS	Beta
NECLIFE this stock	+3.3	+7.0	-7.6	-13.8	-52.0	-59.6	—	0.39	-39.3	—	—	—	—	219	—	—	-11.4	0.96
BLISSGVS	-7.5	+36.6	+123.7	+292.3	+600.7	+478.8	47.5	5.44	11.5	16.8	—	0.00	28.1	6,492	1,005	142	12.9	1.10
VENUSREM	-5.0	-10.3	+43.9	+232.4	+494.9	+234.4	17.4	3.05	16.8	21.9	—	0.00	13.2	2,024	811	116	86.9	0.88
BAFNAPH	+42.5	+93.6	+249.0	+227.1	+429.1	+247.8	—	11.37	—	—	—	—	—	—	—	—	—	0.34
INDSWFTLAB	-9.7	+47.0	+140.6	+226.6	+281.4	+475.1	50.2	2.15	3.2	3.9	—	0.01	32.6	2,974	665	57	6.8	0.79
RUBICON	-16.4	-1.2	+55.1	+136.7	—	—	81.7	18.59	22.4	—	—	0.20	60.5	23,955	1,936	288	17.7	0.34
MOREPENLAB	-5.7	+117.0	+168.0	+134.8	+229.8	+127.0	45.1	5.07	7.9	10.1	—	0.16	39.5	6,324	1,951	140	2.6	1.47
SHILPAMED	-21.1	+37.8	+107.0	+129.0	+406.3	+187.0	55.3	6.38	9.8	11.4	—	0.25	—	16,524	1,682	297	15.3	0.88
LAURUSLABS	-0.2	+27.6	+83.6	+117.8	+401.9	+251.7	86.4	20.51	18.2	17.9	—	0.45	62.2	1.09L	8,839	1,252	23.3	0.74
ZIMLAB	-1.0	+13.5	+51.7	+91.7	+11.4	—	161.3	2.39	2.1	5.5	—	0.42	20.2	708	397	4	0.8	0.75
IOLCP	-14.1	+17.6	+85.1	+83.1	+91.2	+53.0	30.4	2.84	7.9	10.7	—	0.07	19.5	5,115	2,524	168	5.7	1.14

Returns are total over each period, not annualised - 5Y is the whole five-year change. A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Pharma stocks of a similar size

Medico Remedies Aarey Drugs & Pharmaceuticals Medicamen Biotech Wanbury Kronox Lab Sciences Zim Laboratories Kilitch Drugs (India)Anuh Pharma

← All NSE stocks · More Pharma stocks

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →

Prices as of 2026-10-21, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.

For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.

Terms · Privacy · Disclaimer · Refund · Contact